Gastrointestinal Infections News

VIENNA — A combination of a core protein inhibitor and nucleos(t)ide analogue therapy brought hepatitis B virus RNA and DNA below levels of quantification, pointing toward the possibility of a cure, according to a presenter at the International Liver Congress.

VIENNA — A combination of Myrcludex with interferon produced undetectable levels of hepatitis D and significant lowering of hepatitis B virus, according to data presented during the International Liver Congress 2019.

VIENNA — Use of adenovirus derived from chimpanzees showed increased activity and sustainability of T cell activation in an early study of a vaccine for hepatitis C virus, according to new data presented during the International Liver Congress.

VIENNA — Epidemiological modelling showed that scale-up of hepatitis B mother-to-child transmission intervention and treatment in Africa will be as important in the progress to elimination as infant vaccination, according to a presentation at the International Liver Congress 2019.

Recently published data showed that adding bismuth salts to a triple therapy of proton pump inhibitors, amoxicillin and clarithromycin helped eradicate Helicobacter pylori infection.

BALTIMORE — In this video from the National Foundation for Infectious Diseases’ Annual Conference on Vaccinology Research, Anita Zaidi, MBBS, SM, director of the vaccine development, surveillance and enteric and diarrheal diseases programs at the Bill & Melinda Gates Foundation, talks about “some amazing developments” in typhoid control that have occurred over the past 3 years, including a new vaccine.

Results from a recent study showed that a multifaceted intervention including provider and patient education, electronic medical record-enabled best practice alert, and increased hepatitis C treatment capacity significantly increased hepatitis C screening.

Globally, one in four health care facilities lacks basic water service, and one in five has no sanitation service, according to a report by the WHO and UNICEF Joint Monitoring Programme for Water Supply, Sanitation and Hygiene.

The Louisiana Department of Health selected Asegua Therapeutics, a subsidiary of Gilead Sciences, as their pharmaceutical partner in a “subscription style” payment plan designed to provide state residents with access to hepatitis C treatment, according to a press release from the department.

Oral ribaxamase reduces the incidence of Clostridioides difficile infection, or CDI, compared with placebo in patients treated with IV ceftriaxone for lower respiratory tract infections, according to results from a phase 2b trial.